Phase 3 Study to Evaluate the Efficacy and Safety of Elafibranor Versus Placebo in Patients With Nonalcoholic Steatohepatitis (NASH)
Terminated
Genfit
Phase 3
2016-03-01
The primary objectives of this study are to evaluate the effect of Elafibranor treatment
compared to placebo on 1) histological improvement and 2) all-cause mortality and
liver-related outcomes in patients with nonalcoholic steatohepatitis (NASH) and fibrosis.
Study to Evaluate the Efficacy and Safety of Elafibranor in Patients With Primary Biliary Cholangitis (PBC) and Inadequate Response to Ursodeoxycholic Acid
Completed
Genfit
Phase 2
2017-04-05
The primary objective of the study is to compare the effect of daily oral administration of
elafibranor 80mg and 120 mg on change in serum alkaline phosphatase (ALP) to that of placebo
in patients with PBC and inadequate response to Ursodeoxycholic acid (UDCA).
Elafibranor Pharmacokinetic Parameters in Hepatic Impaired Patients
Completed
Syneos Health
Phase 1
2018-12-12
This study is being conducted in order to assess the need for dose adjustment for elafibranor
in patients with hepatic impairment. Pharmacokinetic parameters of elafibranor and its active
metabolite (GFT1007) will be compared in hepatic impaired patients (mild, moderate and severe
according to Child-Pugh categories) versus healthy participants after a single oral
administration of elafibranor 120 mg.
Elafibranor Pharmacokinetic Parameters in Hepatic Impaired Patients
Completed
University of Miami
Phase 1
2018-12-12
This study is being conducted in order to assess the need for dose adjustment for elafibranor
in patients with hepatic impairment. Pharmacokinetic parameters of elafibranor and its active
metabolite (GFT1007) will be compared in hepatic impaired patients (mild, moderate and severe
according to Child-Pugh categories) versus healthy participants after a single oral
administration of elafibranor 120 mg.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
